The HCPFive: Top News for Healthcare Providers from the Week of 06/07

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include new phase 3 data on survodutide in patients with obesity without type 2 diabetes, phase 2b results for elecoglipron in a pair of trials in obesity and type 2 diabetes, the first-ever cardiovascular-kidney-metabolic (CKM) syndrome guideline from the American Heart Association and the American College of Cardiology, the US Food and Drug Administration (FDA)’s addition of bemotrizinol as a permitted active ingredient in its list of over-the-counter sunscreen, and the Agency’s approval of a maintenance regimen of lebrikizumab (Ebglyss) 250 mg for moderate to severe atopic dermatitis.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of June 7, 2026 — let's jump in!

Survodutide Shows Fat Mass Loss, Liver Fat Reductions in Patients With Obesity Without T2D

Phase 3 data presented at the ADA Scientific Sessions 2026 in New Orleans, Louisiana, show survodutide, Boehringer Ingelheim’s investigative glucagon/GLP-1 receptor dual agonist, has demonstrated substantial weight loss and improved metabolic health in patients with obesity or overweight without type 2 diabetes. Carel le Roux, PhD, director of the Metabolic Medicine Group at the University College Dublin School of Medicine and a global coordinating investigator of the study, discussed the implications of these data for survodutide’s investigative future – as well as the patient population it aims to serve.

Elecoglipron Advances to Phase 3, Shows Phase 2 Weight Loss, Glycemic Data

AstraZeneca announced positive phase 2b results for elecoglipron, an investigational oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), across a pair of trials in obesity and type 2 diabetes, paving the way for an extensive phase 3 program. Results from the VISTA and SOLSTICE trials were presented at the ADA 2026 Scientific Sessions in New Orleans and simultaneously published in The Lancet.

In VISTA, adults with obesity or overweight receiving elecoglipron 75 mg achieved an average 10.5% reduction in body weight at 26 weeks versus 0.6% with placebo, with weight loss continuing to 11.8% at 36 weeks. In SOLSTICE, elecoglipron 75 mg reduced HbA1c by an average of 1.9% from baseline at 26 weeks versus 0.2% with placebo, with 90% of treated participants reaching an HbA1c below 7%.

AHA, ACC Issue First-Ever Clinical Guideline for Cardiovascular-Kidney-Metabolic Syndrome

The American Heart Association and the American College of Cardiology jointly issued the first-ever clinical guideline for cardiovascular-kidney-metabolic (CKM) syndrome, identifying excess weight, particularly in the abdomen, as a key driver for the syndrome's development and progress.

Recommendations include screening, prevention and treatment for people with or at risk of developing CKM syndrome. Healthy lifestyle behaviors; medications, including GLP-1-based therapies and SGLT2 inhibitors; and/or metabolic and bariatric surgery, when appropriate, are recommended with the goal of preventing, managing and potentially reversing CKM syndrome progression.

FDA Adds Bemotrizinol as First New Sunscreen Ingredient in Decades

On June 9, 2026, the FDA finalized an order including bemotrizinol as a permitted active ingredient in its list of over-the-counter (OTC) sunscreen products approved for skin cancer protection, marking the first addition of a new active ingredient to the OTC sunscreen monograph since the late 1990s.

According to the Agency, the ingredient has demonstrated low levels of systemic absorption through users’ skin and is considered generally recognized to be both safe and effective (GRASE) for implementation in sunscreen products in adults and children aged 6 months and older. The FDA's final order allows bemotrizinol at concentrations of up to 6%.

FDA Approves Lebrikizumab 8-Week Maintenance Dosing in Atopic Dermatitis

On June 9, 2026, the FDA approved a maintenance regimen of lebrikizumab (Ebglyss) 250 mg administered once every 8 weeks for adults and children aged 12 years and older weighing at least 40 kg with moderate to severe atopic dermatitis.

Lebrikizumab, an interleukin-13 (IL-13) inhibitor, received initial US approval in 2024 as a first-line biologic with once-monthly maintenance dosing and, more recently, long-term data have shown durable disease control with the agent through up to 4 years of continuous treatment.The every-8-week option reduces injection frequency for patients maintaining adequate clinical response.